Welcome to our dedicated page for Mallinckrodt plc news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt plc stock.
Mallinckrodt plc (MNK) delivers specialty pharmaceutical solutions and medical imaging innovations across autoimmune, rare disease, and diagnostic markets. This news hub provides investors and healthcare professionals with essential updates on the company’s strategic developments and regulatory milestones.
Access timely reports on earnings announcements, product approvals, research advancements, and partnership agreements. Our curated collection features official press releases alongside verified third-party coverage of MNK’s activities in specialty generics, contrast media production, and therapeutic pipeline progress.
Key content categories include financial performance updates, manufacturing capacity expansions, intellectual property developments, and compliance-related communications. Track MNK’s progress in neurology, rheumatology, and nephrology treatment innovations through objective reporting of material events.
Bookmark this page for streamlined monitoring of Mallinckrodt’s operational updates and market positioning. Check back regularly for authoritative coverage of this specialty pharma leader’s initiatives in addressing complex healthcare challenges through advanced biopharmaceutical solutions.
Mallinckrodt has announced the presentation of five clinical studies on TERLIVAZ® (terlipressin) at the 2025 Digestive Disease Week (DDW) in San Diego. The research focuses on treating hepatorenal syndrome (HRS) with rapid reduction in kidney function, also known as HRS-AKI.
TERLIVAZ is the first FDA-approved treatment for this rare condition, which affects over 42,000 Americans annually (0.01% of U.S. population). The presentations include one oral presentation and four posters, covering topics such as real-world treatment outcomes, comparative analysis between UK and US patients, and efficacy in patients with alcohol-associated liver disease.
The presentations will take place from May 3-6, 2025, featuring research on transplant waitlist status, treatment comparisons, and benefit-to-risk profiles. Important safety information indicates that TERLIVAZ may cause serious respiratory failure, particularly in patients with volume overload or acute-on-chronic liver failure Grade 3.
Mallinckrodt (MNK) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:30 a.m. ET on the same day.
Investors can participate through multiple channels, including a live call registration system, an audio-only webcast, or through the company's Investor Relations webpage.
Mallinckrodt reported strong financial results for Q4 and FY 2024, achieving the high end of full-year net sales guidance. Full-year net sales grew 6.1% to $2.0 billion, with Acthar® Gel growing 14.2% and Specialty Generics up 15.4%. The company reduced total debt by 47% and net debt by 64%.
Q4 2024 net sales reached $492.1 million, up 4.9% from Q4 2023. The Specialty Brands segment reported $265.6 million in net sales, while Specialty Generics achieved $226.5 million. Q4 net income was $612.8 million, with Adjusted EBITDA at $124.2 million.
For 2025, Mallinckrodt expects net sales between $1.7-1.8 billion and Adjusted EBITDA of $480-520 million. The company's performance was driven by Acthar Gel's successful SelfJect™ device launch and accelerated uptake of INOmax® EVOLVE™ DS delivery system.
Mallinckrodt and Endo have announced a strategic merger to create a global pharmaceuticals leader through a stock and cash transaction. The deal, expected to close in H2 2025, will see Endo shareholders receive $80 million in cash and own 49.9% of the combined entity, while Mallinckrodt shareholders will own 50.1%.
The combined company, to be listed on the NYSE, projects $3.6 billion in 2025 revenue and $1.2 billion in Adjusted EBITDA. The merger aims to generate at least $150 million in annual operating synergies by Year 3 and approximately $75 million in Year 1.
Key aspects include a net leverage of 2.3x at close, 17 manufacturing facilities, 30 distribution centers, and approximately 5,700 employees. The companies plan to combine and later separate their generics and sterile injectables businesses. Siggi Olafsson will serve as CEO of the combined entity, with Paul Efron as Board Chair.
Mallinckrodt plc (MNK), a global specialty pharmaceutical company, has rescheduled its fourth quarter and fiscal year 2024 financial results release to Thursday, March 13, 2025, before market open. The earnings conference call for investors will begin at 8:00 a.m. ET.
The company operates through two main segments: Specialty Brands, focusing on autoimmune and rare diseases in areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology, along with neonatal respiratory critical care therapies and gastrointestinal products; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
Mallinckrodt has scheduled the release of its fourth quarter and fiscal year 2024 financial results for Tuesday, March 11, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:00 a.m. ET on the same day. Participants can access the call through registration links provided, with options including an audio-only webcast and replay availability through the company's Investor Relations webpage.
Mallinckrodt has completed the sale of its Therakos business to CVC Capital Partners Fund IX for $925 million. The transaction will enable the company to reduce its net debt by more than 60% using the net proceeds. The divestiture aligns with Mallinckrodt's strategic priorities to optimize its capital structure and focus on core strengths. Lazard acted as financial advisor, while Wachtell, Lipton, Rosen & Katz served as primary legal counsel for the transaction.
Mallinckrodt presented data on TERLIVAZ (terlipressin) for hepatorenal syndrome (HRS) at the 2024 AASLD Annual Meeting. The research analyzed pooled data from three Phase 3 studies, evaluating HRS reversal after 12 doses. Results showed 33.6% reversal rate in the TERLIVAZ group versus 16.8% in placebo. Notably, 94.9% of patients achieving HRS reversal required more than 12 doses. TERLIVAZ is the first FDA-approved treatment for improving kidney function in adults with HRS, a condition affecting approximately 42,000 Americans annually.
Mallinckrodt plc has announced its participation in the upcoming Jefferies London Healthcare Conference. Siggi Olafsson, President and Chief Executive Officer, will deliver a presentation on Tuesday, November 19, 2024, at 9:30 a.m. GMT/4:30 a.m. ET. For those unable to attend in person, a webcast will be available online, with a replay option provided after the event.
Mallinckrodt reported Q3 2024 net sales of $505.5 million, up 1.7% year-over-year. The company raised its full-year Adjusted EBITDA guidance to $590-620 million while reaffirming net sales guidance of $1.9-2.0 billion. Acthar Gel achieved its third consecutive quarter of growth, with sales up 3.5% to $126.4 million, leading to expectations of approximately 10% growth for full-year 2024. The Specialty Generics segment reported 4.1% growth to $219.5 million. The company expects to reduce net debt by more than 60% in Q4 following the sale of Therakos business for $925 million to CVC Capital Partners.
